Literature DB >> 18757300

A cross-talk between stromal cell-derived factor-1 and transforming growth factor-beta controls the quiescence/cycling switch of CD34(+) progenitors through FoxO3 and mammalian target of rapamycin.

Aurélie Chabanon1, Christophe Desterke, Emilie Rodenburger, Denis Clay, Bernadette Guerton, Laetitia Boutin, Annelise Bennaceur-Griscelli, Olivier Pierre-Louis, Georges Uzan, Lucile Abecassis, Marie-Françoise Bourgeade, Jean-Jacques Lataillade, Marie-Caroline Le Bousse-Kerdilès.   

Abstract

Cell cycle regulation plays a fundamental role in stem cell biology. A balance between quiescence and proliferation of hematopoietic stem cells in interaction with the microenvironment is critical for sustaining long-term hematopoiesis and for protection against stress. We analyzed the molecular mechanisms by which stromal cell-derived factor-1 (SDF-1) exhibited a cell cycle-promoting effect and interacted with transforming growth factor-beta (TGF-beta), which has negative effects on cell cycle orchestration of human hematopoietic CD34(+) progenitor cells. We demonstrated that a low concentration of SDF-1 modulated the expression of key cell cycle regulators such as cyclins, cyclin-dependent kinase inhibitors, and TGF-beta target genes, confirming its cell cycle-promoting effect. We showed that a cross-talk between SDF-1- and TGF-beta-related signaling pathways involving phosphatidylinositol 3-kinase (PI3K)/Akt phosphorylation participated in the control of CD34(+) cell cycling. We demonstrated a pivotal role of two downstream effectors of the PI3K/Akt pathway, FoxO3a and mammalian target of rapamycin, as connectors in the SDF-1-/TGF-beta-induced control of the cycling/quiescence switch and proposed a model integrating a dialogue between the two molecules in cell cycle progression. Our data shed new light on the signaling pathways involved in SDF-1 cell cycle-promoting activity and suggest that the balance between SDF-1- and TGF-beta-activated pathways is critical for the regulation of hematopoietic progenitor cell cycle status.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757300     DOI: 10.1634/stemcells.2008-0219

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  20 in total

1.  RepSox slows decay of CD34+ acute myeloid leukemia cells and decreases T cell immunoglobulin mucin-3 expression.

Authors:  Audrey N Jajosky; James E Coad; Jeffrey A Vos; Karen H Martin; Jamie R Senft; Sharon L Wenger; Laura F Gibson
Journal:  Stem Cells Transl Med       Date:  2014-05-22       Impact factor: 6.940

2.  Hematopoietic stem cell niche is a potential therapeutic target for bone metastatic tumors.

Authors:  Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Clin Cancer Res       Date:  2011-06-15       Impact factor: 12.531

Review 3.  TGF-β signaling and its role in the regulation of hematopoietic stem cells.

Authors:  Anuradha Vaidya; Vaijayanti P Kale
Journal:  Syst Synth Biol       Date:  2015-01-29

4.  Association of TGFβ signaling with the maintenance of a quiescent stem cell niche in human oral mucosa.

Authors:  Claudia D Andl; Grégoire F Le Bras; Holli Loomans; Annette S Kim; Linli Zhou; Yuhang Zhang; Thomas Andl
Journal:  Histochem Cell Biol       Date:  2016-08-02       Impact factor: 4.304

Review 5.  Cell cycle regulation of hematopoietic stem or progenitor cells.

Authors:  Sha Hao; Chen Chen; Tao Cheng
Journal:  Int J Hematol       Date:  2016-03-23       Impact factor: 2.490

6.  Concerted loss of TGFβ-mediated proliferation control and E-cadherin disrupts epithelial homeostasis and causes oral squamous cell carcinoma.

Authors:  Thomas Andl; Grégoire F Le Bras; Nicole F Richards; Gillian L Allison; Holli A Loomans; M Kay Washington; Frank Revetta; Rebecca K Lee; Chase Taylor; Harold L Moses; Claudia D Andl
Journal:  Carcinogenesis       Date:  2014-09-18       Impact factor: 4.944

7.  Distinct hematopoietic stem cell subtypes are differentially regulated by TGF-beta1.

Authors:  Grant A Challen; Nathan C Boles; Stuart M Chambers; Margaret A Goodell
Journal:  Cell Stem Cell       Date:  2010-03-05       Impact factor: 24.633

8.  Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.

Authors:  Ilaria Ceglia; Amylou C Dueck; Francesca Masiello; Fabrizio Martelli; Wu He; Giulia Federici; Emanuel F Petricoin; Ann Zeuner; Camelia Iancu-Rubin; Rona Weinberg; Ronald Hoffman; John Mascarenhas; Anna Rita Migliaccio
Journal:  Exp Hematol       Date:  2016-08-31       Impact factor: 3.084

9.  MicroRNA-23a mediates post-transcriptional regulation of CXCL12 in bone marrow stromal cells.

Authors:  Laleh S Arabanian; Fernando A Fierro; Friedrich Stölzel; Carolin Heder; David M Poitz; Ruth H Strasser; Manja Wobus; Martin Borhäuser; Ruben A Ferrer; Uwe Platzbecker; Matthias Schieker; Denitsa Docheva; Gerhard Ehninger; Thomas Illmer
Journal:  Haematologica       Date:  2014-02-28       Impact factor: 9.941

10.  Cardiomyocyte-derived CXCL12 is not involved in cardiogenesis but plays a crucial role in myocardial infarction.

Authors:  Silke Mühlstedt; Santhosh K Ghadge; Johan Duchene; Fatimunnisa Qadri; Anne Järve; Larisa Vilianovich; Elena Popova; Andreas Pohlmann; Thoralf Niendorf; Philipp Boyé; Cemil Özcelik; Michael Bader
Journal:  J Mol Med (Berl)       Date:  2016-06-01       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.